2023 BrainChip Discussion, page-2898

Mate, I hope you are wrong about the take-over, I myself would not
want to sell my shares in a take- over for only $2.50. With the way
things are going with all the partners joining up with BRN. And I think
there will be a lot more Companies in the future. Once Revenue starts
to come in after the products start selling, this Chip will keep just keeping on.
So with this in mind within a few years' time with the Royalties from these
products will start to produce Dividends.

BrainChip's Partners List (Thanks to FF in his Diligence) and
has been verified by the Company.)

Ai Labs
ARM
ANT 61
BIOTOME
BLUE RIDGE ENVISIONEERING
CVEDIA
EDGE IMPULSE
EMOTION 3D
FORD
GLOBAL FOUNDRIES
IPRO
INFORMATION SYSTEM LABORATORIES
INTEL
INTELLISENSE SYSTEMS
LORSER INDUSTRIES
MEGACHIP
MERCEDES BENZ
MOSCHIP
NANOSE
NASA
NUMEN
NVISO
OCULI
PROPHESEE
QUANTUM VENTURA
RENESAS
SALESLINK
SiFIVE
SOCIONEXT
TATA CONSULTING SERVICES
TEKSUN
VALEO
VORAGO
VVDN

Then there are the Universities that are doing courses with AKIDA Technology.
ARIZONA STATE UNIVERSITY
CARNEGIE MELLON UNIVERSITY
DREXEL UNIVERSITY
UNIVERSITY OF OKLAHOMA
ROCHESTER INSTITUTE OF TECHNOLOGY

Now these Universities and Technology Institution would not waste their time and money
on this Technology unless they know that this is going to be the future for the way Companies
will use The Edge, and BRN is up there at the front of the line with AKIDA. I am sure that
there will be more Universities in the future that will take on this Technology to teach.
Well in saying all of this, it is only my opinion and what would I know, so please
do your own research. And please do not believe all the down ramping, as half the people
down ramping have a motive and the other half would have NO idea, and for the up ramping
people take it with a grain of salt. But there are some good posters here that do put you on
to internet articles that are very Interesting and I thank them for that.
So really it all comes down to PATIENCE to wait for the REVENUE to start to come in.